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ABSTRACT 
 
 A STUDY ON FACTORS PREDICTING THE OUTCOME OF 
PERFORATED PEPTIC ULCER 
Place: Department of General Surgery, Madras Medical College and 
Rajivgandhi Government General Hospital, Chennai. 
BACKGROUND AND AIM: 
With the introduction of H2 receptor antagonists and proton pump inhibitors, 
the incidence of elective surgery for peptic ulcer (PU) diseases has decreased, 
although complications of PU such as perforation and bleeding have remained 
fairly constant. The purpose of this study was to identify the risk factors that 
predict morbidity and mortality in patients with perforated Peptic Ulcer 
METHODS 
The following factors were recorded for 100 patients diagnosed and operated for 
perforated peptic ulcer and were analyzed in terms of morbidity and mortality: 
age, sex, personal habits of smoking and consuming alcohol, NSAID usage, 
past peptic ulcer history, co morbid illnesses, the duration of pain, duration 
between pain and surgery, duration between admission and surgery, surgery 
duration, shock and American Society of Anesthesiologist score, size, site of 
perforation, contamination, procedure and complications following the surgery. 
RESULTS 
Age of 60 years and above had mortality of 46% and also this mortality is high 
within the first 48 hrs and up to 7 days. Average duration of hospital stay was 7 
to 14 days. Female sex was more related to severe disease and mortality 
(100%). Duration of pain of 3 days had 35.7% and 4 or more 50% mortality. 
82% of the patients had past history of peptic ulcer and on and off treatment. 
16% of patients had history of NSAID usage before perforation. 48% of patients 
had the habit of both smoking and alcohol and 40% are neither smoking nor 
alcoholic. On physical examination 96% had respiratory distress, 80% had 
anemia, 38% had tachycardia, 26% both hypotension and tachycardia, and 36% 
had normal pulse and blood pressure. 94% had signs of peritonitis. 80% showed 
air under diaphragm in chest X ray. Preoperative lower respiratory infection had 
40% mortality. Duration between pain and surgery that is preoperative delay of 
48 to 72 hours had 31% and more than 72 hrs had 32% mortality. ASA score of 
4 and 5 had 100% mortality and score of 3 had 64%. Gastric perforation (30%) 
has more mortality than duodenal (20%) perforation. Size of perforation more 
than 1 cm has 42% mortality. Contamination of more than 1 litre had related to 
44% of death. Duration of the surgery more than 2 hours had significant effect 
on the mortality. 32% were in need of ventilator support and 24% were in need 
of circulatory support. 76% of patients had adequate renal function. 46% of the 
patients developed wound infection and 26% had wound dehiscence and 
underwent secondary suturing. Post operatively 20% patients had lower 
respiratory infection and 10% had ARDS leading to death. 24% of the patient 
had acute kidney injury and treated with supportive treatment. 14% of patients 
had developed multiple organ dysfunctions and died. Sepsis leading to shock 
and multiple organ dysfunctions is a cause of death.  
CONCLUSION 
The following factors were associated with morbidity and mortality; Age more 
than 60 years, duration between initial pain and surgery of more than 48 hours, 
class III or more shock, ASA score of 3and more, size of more than 1 cm and 
contamination of more than 1 litre and the following factors were associated 
with mortality; Preoperative lower respiratory infection, duration of the surgery, 
Post operative lower respiratory infection, and Acute respiratory distress 
syndrome. 
 
Key words: perforated peptic ulcer, peptic ulcer perforation.  
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INTRODUCTION 
Perforation is one of the complications of peptic ulcer disease. The 
development and use of gastric anti secretory agents like H2 receptor blockers, 
proton pump inhibitors together with the understanding of Helicobacter pylori 
infection as a cause of disease and its eradication with the drug therapy has 
resulted in high chance of curing peptic ulcer disease and also preventing  
recurrence of peptic ulcer.  
As a result, there has been a marked decrease in the number of elective 
surgery for acid reduction in patients with uncomplicated peptic ulcer and there 
is fall in the incidence of peptic ulcer disease in recent years, globally
1
.  
Though the number of patients admitted in emergency department for 
perforated peptic ulcer and emergency surgery for the same has not undergone 
similar decline, and it remain a significant health problem
1-4
.  
 There is high risk of emergency for perforated peptic ulcer and high rate 
of postoperative complication which is between 21% to 43%
5, 6
. The morbidity 
and mortality following the emergency surgery for peptic ulcer perforation and 
risk factors associated with peptic ulcer perforation were studied by several 
studies. There are multiple factors which are influencing the outcome of surgery 
for perforated peptic ulcer. Inspite of plenty of evidence in the literature, the 
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knowledge about factors which affect the morbidity and mortality that occurs 
after perforated peptic ulcer is limited.  
 We have conducted a prospective study in 100 patients admitted for 
perforated peptic ulcer from January 2013 to October 2013. The rationale of this 
study is to evaluate the factors that influence the mortality and morbidity in 
patients operated for peptic ulcer perforation. 
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AIM OF THE STUDY 
The aims of the study are 
1. To study the age group, sex, personal habits of smoking and consuming 
alcohol, NSAID usage, past peptic ulcer history and  co morbid illnesses 
and its relationship with outcome of peptic ulcer perforation. 
2. To study the duration of pain, duration between pain and surgery, 
duration between admission and surgery, surgery duration and its relation 
to morbidity and mortality. 
3. To study the shock and ASA score and effect on the mortality and 
morbidity in peptic ulcer perforation 
4. To study biochemical and hematological factors predicting the final 
outcome of perforated peptic ulcer 
5. To study size, site of perforation, contamination and procedure and 
mortality and morbidity in peptic ulcer perforation 
6. To study the complications following the surgery for peptic ulcer 
perforation. 
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REVIEW OF LITERATURE 
For thousands of years healthy people have had acute abdominal pain, 
nausea, vomiting and diarrhoea followed by death in a few hours or days. Often 
these symptoms were contributed to poisoning and people have been sent to 
prison for this
7
.Henriette-Anne daughter of King Charles I, died suddenly in 
1670 at age of 26 after a day of abdominal pain and tenderness. Since poisoning 
was suspected autopsy was performed which revealed peritonitis and a small 
opening in the anterior wall of the stomach. However, the doctors had never 
heard of a perforated peptic ulcer and attributed the opening in the stomach to 
the knife of the dissector 
7, 8
. Necropsies were allowed since 1500 and became 
more routine between 1600 and 1800 
8, 9
. As a consequence more often 
perforation of the stomach was observed.  
The surgeon Johan Mikulicz-Radecki (1850-1905), often referred to as 
the first surgeon who closed a perforated peptic ulcer by simple closure said: 
“Every doctor, faced with a perforated of the stomach or intestine, must 
consider opening the abdomen, sewing up the hole, and averting a possible 
inflammation by careful cleansing of the abdominal cavity” 10.  
The treatment since has not changed much, still consisting of closure of 
the perforation primarily by single stitch suture and a convenient tag of adjacent 
omentum on top of this 
11 - 14
. Although this therapy sounds very simple still 
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PPU remains a dangerous surgical condition, associated with high morbidity 
and mortality, not to be underestimated 
15
. 
CLINICAL PRESENTATION AND INVESTIGATION 
In 1843 Edward Crisp was the first to report 50 cases of PPU and 
accurately summarized the clinical aspects of perforation; concluding: “The 
symptoms are so typical, I hardly believe it possible that anyone can fail to 
make the correct diagnosis.” 16.  
Patients with PPU have a typical history of sudden onset of acute, sharp 
pain usually located in the epigastric area and sometimes with referred shoulder 
pain, indicating free air under the diaphragm 
17
. Bases on collected data from 52 
papers on PPU clinical characteristics have been summarized in Table 1.  
Table 1. Clinical characteristics of patients with perforated peptic ulcer disease 
[18, 19, 22, 37, 47-49, 51, 55, 57, 59, 64] 
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The typical patient with PPU is male with an average age of 45 years. He 
may have peptic ulcer disease history (29%), or usage of nonsteroidal anti-
inflammatory drugs (NSAIDs) (20%). Nausea and vomiting are present in 50% 
of cases.  
At physical examination pulse rate increased, but seldom goes beyond 90 
beats per minute. About 5-10% of patients experience shock with a mean 
arterial pressure of less than 80 mmHg 
18
. Hypotension and high fever are late 
findings. Obliteration or complete absence of liver dullness was only noted in 
37%, so as a diagnostic tool, this has its limitations 
13
.  
In blood analysis a moderate leucocytoses will be found. Main reason for 
taking a blood sample is excluding other diagnosis like for instance pancreatitis 
10
. An X-ray of the abdomen/thorax in standing position will reveal free air 
under diaphragm in about 80-85 % 
13, 19
. Some centres perform abdominal 
ultrasonography, or abdomen contrast enhanced computerized tomography 
scans with oral contrast 
20
. 80-90% of cases are correctly diagnosed with current 
radiological techniques 
18
.  
As soon as diagnosis is made resuscitation is started with large volume 
crystalloids, nasogastric suction to empty the stomach; and administration of 
broadspectrum antibiotics 
19, 21
. When PPU has been diagnosed, there are a few 
different therapeutic options to be taken into consideration 
18
. First of all it must 
be evaluated if the patients are suitable for surgery or should conservative 
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treatment be considered instead. If surgery is indicated, is simple closure with or 
without omentoplasty sufficient or is there a need for definitive ulcer surgery 
and if there is a need for definitive surgery, which specific operation is 
indicated? Finally, can the operation be performed laparoscopically or are there 
risk factors that would made laparotomy a safer option? 
18, 22
. 
PATHOGENESIS 
A peptic ulcer is defined as disruption in the integrity and discontinuity of 
mucosa of duodenum and/or stomach which lead to a local defect with active 
inflammation. These ulcers are often chronic in nature. Peptic Ulcer Disease 
includes both gastric and duodenal ulcers.  
Ulcers, breaks in the mucosal surface and size >5 mm, with depth 
extending up to the submucosa. The pathogenesis, diagnosis and treatment are 
common in both duodenal ulcers (DUs) and gastric ulcers (GUs); but several 
factors distinguish them from one another. 
The pathogenesis of PUD is a complex scenario involving an imbalance 
between defensive and aggressive factors. The Defensive factors include 
Mucus-bicarbonate layer, Prostaglandins, Cellular renovation, and Blood flow   
The aggressive factors include Hydrochloric acid, Pepsin, Ethanol, Bile salts, 
Some medications including NSAIDs, etc. 
21,
 Cocaine
18
.  
 Helicobacter pylori infection and NSAIDs have been identified as the two 
main causes of peptic ulcer 
23 
in recent years.  
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Mucosal defense system 
 It is a three-level barrier system (Figure 3), composed of  
 Pre epithelial,  
 Epithelial and  
 Sub epithelial elements.  
Figure 1 
 
Pre epithelial system 
It is a mucus-bicarbonate-phospholipid layer. It is the first line of defense 
in preventing ulcer formation. This is a physicochemical barrier to multiple 
molecules, including hydrogen ions protecting the mucosa.  
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 Mucus is secreted by gastroduodenal surface epithelial cells in a regulated 
fashion. Contents of mucus are of 95%water and a mixture of mucin a 
glycoprotein and phospholipids. This mucous gel acts as a nonstirred 
water layer which impedes diffusion of ions and molecules including 
pepsin.  
 Bicarbonate, secreted by surface epithelial cells of the gastroduodenal 
mucosa in a regulated manner. Bicarbonate is secreted into the mucous 
gel. Bicarbonate forms a pH from 1 to 2 at the gastric luminal surface and 
reaching 6 to 7 along the epithelial cell surface. 
Epithelial barrier 
Surface epithelial cells provide the next line of defense in protecting the 
mucosa. They act by producing mucus, bicarbonate and epithelial cell ionic 
transporters and intracellular tight junctions. These ionic transporters maintain 
intracellular pH.  
Surface epithelial cells generate heat shock proteins that prevent protein 
denaturation and protect cells from increased temperature, cytotoxic agents, or 
oxidative stress. Epithelial cells also generate trefoil factor family peptides and 
cathecidins, which also play a role in surface cell protection and regeneration.  
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Restitution: when the preepithelial barrier is breached, gastric epithelial 
cells along the site of mucosal injury can migrate and restore a damaged region. 
This restitution process occurs independent of cell division. It requires  
 Uninterrupted blood flow  
 An alkaline pH in the surrounding environment.  
 Several growth factors modulate restitution process which include 
epidermal growth factor (EGF), transforming growth factor (TGF), and 
basic fibroblast growth factor (FGF),  
 Larger defects that are not effectively repaired by restitution require cell 
proliferation.  
Epithelial cell regeneration  
This is regulated by prostaglandins and growth factors. Growth factors 
are EGF and TGF-. During regeneration angiogenesis occurs within the injured 
micro vascular bed. Both FGF and vascular endothelial growth factor (VEGF) 
are important regulators of angiogenesis in the gastric mucosa. 
Sub epithelial system  
It is defense and repair system.  
Key component - An elaborate microvascular system within the gastric 
submucosa  
11 
 
Functions  
o Provides bicarbonate to neutralize the acid generated by the parietal cell.  
o Provides adequate supply of micronutrients and oxygen  
o Removes toxic metabolic by products. 
Prostaglandins 
 Prostaglandins play a central role in defense and repair. The gastric 
mucosa contains abundant levels of prostaglandins. 
Functions 
o Regulate the release of mucosal bicarbonate and mucus,  
o Inhibit parietal cell secretion  
o Maintains mucosal blood flow  
o Epithelial cell restitution.  
Nitric oxide (NO) 
 It maintains the gastric mucosal integrity. The key enzyme NO synthase 
is constitutively expressed in the mucosa which contributes to cytoprotection by  
o Stimulating gastric mucus secretion,  
o Increases mucosal blood flow and  
o Maintains epithelial cell barrier function.  
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 The central nervous system (CNS) and hormonal factors also play a role 
in regulating mucosal defense through multiple pathways. 
There are three clinical phases in the process of PPU
4
.  
 Phase 1: Chemical peritonitis/ contamination 
The perforation results in chemical peritonitis.  
Gastroduodenal contents are sterilized by acid. In conditions like gastric 
cancer or when gastric acid is reduced by treatment, bacteria and fungi 
grow in the stomach and duodenum is present in the peritoneum resulting 
in contamination.  
 Phase 2: Intermediate stage 
There is some spontaneous relief of pain after 6 to 12 hours. This is 
probably due to the dilution of the gastroduodenal contents leaked in to 
the peritoneum, irritating in character by ensuing peritoneal exudates.  
 Phase 3: Intra-abdominal infection:  
Intra-abdominal infection occurs after 12-24 hrs. 
EPIDEMIOLOGY 
 Perforation occurs in 2-10% of patients with PUD and accounts for more 
than 70% of deaths associated with PUD. Often perforation is the first clinical 
presentation of PUD 
24
. The incidence of duodenal perforation is 7-10 cases/ 
100.000 adults per year. 
15, 21, 22, 25-28
.  
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 The perforation site usually involves anterior wall of the duodenum 
(60%), Antrum (20%) and Lesser-curvature gastric ulcers (20%) 
25
.  
Gastric ulcers are associated with higher mortality and a greater morbidity than 
duodenal ulcers due to haemorrhage, perforation and obstruction 
23
.  
PPU used to be a disorder mainly of younger patients (predominantly 
males), but recently the age of PPU patients is increasing (predominantly 
females) 
22, 26
. Current peak age is 40-60 years 
22
.  
The need for surgery for PPU has remained stable or even increased and 
the mortality following peptic ulcer perforation surgery have not decreased 
since the introduction of H2 receptor antagonists. The peptic ulcers are still 
responsible for about 20.000-30.000 deaths per year in Europe 
25, 29
. This may 
be due to an increase in use of aspirin and/ or NSAID’s 18.  
THE ROLE OF HELICOBACTER PYLORI 
In 1982 Barry J Marshall and Robin Warren discovered the role of 
H.pylori in gastric and duodenal ulcers, until this, stress and life style factors 
were believed to be the most important factor contributing to PUD and PPU 
30
. 
H.pylori infection can be hold responsible 
23, 30 
for more than 90% of duodenal 
ulcers and up to 80% of gastric ulcers.  
H.pylori infection and the accompanying inflammation decreases antral 
somatostatin and disrupt the inhibitory control of gastrin release. This is more 
marked in a cagA-positive strain 
25 
organism infection. This results in increase 
14 
 
in gastrin release and gastric acid secretion which induces PUD 
25
.  The 
infection with H.pylori seems to be acquired in early childhood. The immune 
system does not contribute to the healing.
9, 23
. H.pylori is not only located on the 
surface of the gastric mucosa but also in the layer of mucus protecting it causing 
difficulty in its eradication. The national institutes of Health Consensus 
Development Panel on Helicobacter pylori in PUD recommended that ulcer 
patients positive for H.pylori should be treated with antimicrobial agents 
31
. The 
type, number of drugs given and treatment duration differ enormously 
31
. 
Although the problem of antibiotic resistance of H.pylori is increasing, 
combination therapies can achieve eradication rates of 80% or more 
25, 32
. 
According to the Maastricht III consensus report first line treatment for H.pylori 
infection should be triple therapy which should compromise a proton pump 
inhibitor (PPI) plus clarithromycin plus amoxicillin or metronidazole 
23, 33. 
Monotherapy by just giving antibiotics has proven not to be successful (<30% 
eradication rate) 
23
.  
Peptic ulcer is diagnosed by upper gastro intestinal endoscopy, but 
patients do not tolerate well 
28
. Carbon 13-urea breath test is expensive, but 
represents a reliable indicator of H.pylori infection. The preferred method to 
diagnose H.pylori is by taking peroperative biopsies 
28
. Even in patients with 
PPU and NSAID usage, looking for the presence of H.pylori is advisable, since 
it can be eradicated easily.  
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To avoid missing gastric cancer, gastroendoscopy should be performed in 
patients > 45 yrs with alarming features like weight loss, anaemia, or dysphagia 
23
. 
NSAID 
 The use of nonsteroidal antiinflammatory drugs attributed to about one of 
four peptic ulcer perforations and in the elderly it is an important risk factor 
62
. 
Patients concurrently ingesting corticosteroids and NSAIDs had a risk for peptic 
ulcer disease that was 15 times greater than that of nonusers of either drug
 63
. 
CURRENT MANAGEMENT PPU 
Non operative management - conservative treatment  
Simple suture open repair technique 
Definitive surgery or 
Laparascopic surgery 
NON OPERATIVE CONSERVATIVE MANAGEMENT 
 This is known as the Taylor method. 
Patients are treated with 
 Nasogastric aspiration,  
 Antibiotics,  
 Intravenous fluids and  
 H.pylori triple therapy 29, 32.  
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 Effective gastric decompression and continuous drainage will enhance 
self healing described by Taylor 
15, 31
. Perforations of the stomach were filled 
up by adhesions to the surrounding viscera which prevented leakage from the 
stomach into the peritoneum described by Crisp
31
. Since, many reports have 
been published on this topic, with different success rates 
15
. It has been 
estimated that about 40-80% of the perforations will seal spontaneously and 
overall morbidity and mortality are comparable 
25, 29, 31, 34
.  
Pre operative delay beyond 12hours after the onset of clinical symptoms 
will worsen the outcome in PPU 
15, 25
. Also in patients > 70 years conservative 
treatment is unsuccessful with a failure rate as high as 67% 
15, 34
. Shock at 
admission and conservative treatment were associated with a high mortality 
rate (64%) 
15, 29
.  
Patients can be selected for conservative treatment by performing a 
gastroduodenogram by Donovan 
29
. Non surgical treatment in these patients, 
who had proven sealing of their perforation site was safe, only resulted in 3% 
intraabdominal abscess formation and < 2% repeat leak 
29
.  
The advantages of conservative treatment are  
 Avoidance of operation with associated morbidity caused by surgery and 
anesthesia,  
17 
 
 Reduction in formation of intraabdominal adhesion induced by surgery 
which makes elective surgery for PUD or for other indications in a later 
phase less complicated and  
 Hospital stay might be shorter 35. However, there are also studies that 
showed a prolonged hospital stay after conservative treatment 
19, 25
.  
Disadvantages are  
 A higher mortality rate in case conservative treatment fails.  
 Lack of the benefit of laparoscopy or laparotomy as a diagnostic tool in 
case the patient was misdiagnosed 
34, 35
.  
Figure 2 : Gastric Antral perforation 
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Figure 3 : Duodenum-Part 1 Perforation 
 
 Finally one always has to bear in mind that PPU can be a symptom of 
gastric cancer, so if conservative treatment has been chosen after a few weeks 
endoscopy should be performed 
15, 34
.  
For conclusion one can say that non operative treatment is limited to 
patients < 70 years, not eligible for surgical repair due to associated morbidity, 
with documented contrast studies showing that the perforation has completely 
sealed. When the patients is in shock or is the time point between perforation 
and “start treatment” > 12 hours simple closure should be first choice of 
treatment. 
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SIMPLE SUTURE OPEN REPAIR TECHNIQUE 
All surgical procedures start by giving prophylactic antibiotics at 
induction of anesthesia. In conventional surgery an upper midline incision is 
performed. Identification of the site of perforation is not always easy: 
sometimes a perforation has occurred at the dorsal site of the stomach, only to 
be detected after opening of the lesser sac through the gastrocolic ligament. 
Also double perforations can occur. In case of a gastric ulcer a biopsy is taken 
to exclude gastric cancer.  
Simple closure of the perforation can be done in different ways (f3igure 
4): 
1. Simple closure of the perforation by interrupted sutures without 
omentoplasty or free omental patch,  
2. Omentoplasty - Simple closure of the perforation with a pedicled 
omentum sutured on top of the repair,  
3. A pedicled omental plug drawn into the perforation after which the 
sutures are tied over it and  
4. The free omental patch after Graham.  
The repair can be tested by either filling the abdomen with warm saline and 
inflating some air into the nasogastric tube. If no bubbles appear, the perforation 
has been sealed appropriate. Also dye can be injected through the nasogastric 
tube
36
.  
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Thorough peritoneal toilet  is then performed. A drain is not routinely left 
37
. The abdominal wound can be infiltrated with bupivacaine 0.25% at the end 
of the procedure. 
 
Figure 4: Different suture techniques for closing perforation 
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Omentoplasty or omental patch: necessary or not? Cellan-Jones published 
an article in 1929 entitled “a rapid method of treatment in perforated duodenal 
ulcers”. Treatment of choice at that time was, after excision of friable edges if 
indicated, the application of purse string sutures and on top an omental graft 
38
. 
An encountered problem was narrowing of the duodenum. To avoid this, he 
suggested omentoplasty without primary closing of the defect. His technique 
consisted of placing 4-6 sutures, selecting a long omental strand passing a fine 
suture through it, the tip of the strand is then anchored in the region of the 
perforation and finally the sutures are tied off 
38
. It was not until 1937 that 
Graham published his results with a free omental graft 
39
. He placed three 
sutures with a piece of free omentum laid over these sutures, which are then 
tied. No attempt is made to actually close the perforation 
39
. 
 
 The omental graft provides the stimulus for fibrin formation. His 
approach has been the golden standard since 
40
. Very often surgeons mention 
they used a Graham patch, but they actually mean they used the pedicled 
omental patch described by Cellan-Jones 
39
. Schein could not have outlined it 
any clearer: “Do not stitch the perforation but plug it with viable omentum and 
patch a perforated ulcer if you can, if you cannot, then you must resect” 10.  
Irrigation of the peritoneal cavity Although some surgeons doubt the 
usefulness of irrigation, nothing has been found in literature supporting this 
theory. General it is one of the most important parts during the surgery 
22 
 
procedure and irrigation with 6-10 litres and even up to 30 litres of warm saline 
are recommended 
22
. However the rational for routinely use of intra-operative 
peritoneal lavage seems to be more a historical based custom lacking any 
evidence based support 
41
.  
Drainage or not There seems to be no unanimity of opinion on this topic 
22, 36
. In a questionnaire 80% of the surgeons responded that they would not 
leave a drain 
36
. A drain will not reduce the incidence of intraabdominal fluid 
collections or abscesses 
36
. On the other hand the drain site can become infected 
(10%) and can cause intestinal obstruction 
36, 42
. Often a drain is left as a 
sentinel. However, in case of suspected leakage a CT- scan will provide all the 
information needed, probably better than a non-productive drain.  
DEFINITIVE SURGERY  
Indications for elective surgery are still not defined 
25
. The number of elective 
procedures performed for PUD have declined with more than 70% since the 
80’s 25, 28. The results of a questionnaire with 607 responders showed that only 
0.3% of the surgeons routinely perform a vagotomy for duodenal ulcer 
complications and 54.5% mentioned they never include it 
43
.  
Reasons for decline in definitive ulcer surgery are:  
 Lower recurrence rate of PUD and PPU because of good results of 
H.pylori eradication and elimination of NSAID use.  
23 
 
 Patients nowadays operated for PPU are older with higher surgical risk 
which makes them less suitable candidates for definitive ulcer surgery.  
 Finally many surgeons practicing today have limited experience with 
definitive ulcer operations 
28
.  
Patients in whom definitive ulcer surgery should be considered are  
 Those with PPU who are found to be H.pylori negative, or  
 Those with recurrent ulcers despite triple therapy 18, 25, 31, 44, 45.  
In these patients a parietal cell vagotomy is recommended if necessary 
combined with gastrojejunostomy 
46
.  
LAPAROSCOPY  
Since the 90’s laparoscopic closure of a perforated peptic ulcer has 
been described. Laparoscopic surgery offers several advantages.   
Advantages  
o Minimal invasive diagnostic tool 47. 
o Postoperative pain reduction and less consumption of analgesics and  
o A reduction in hospital stay 48.  
o A reduction in wound infections, burst abdomen and incisional hernia due 
to shorter scars has been noted 
32, 48
.  
o Avoiding upper laparotomy might lower the incidence of postoperative 
ileus and chest infections 
32, 48
.  
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Drawbacks are  
o A prolonged operating time,  
o Higher incidence of re-operations due to leakage at the repair site and  
o A higher incidence of intra-abdominal collection secondary to inadequate 
lavage 
32, 48, 49
.  
 If the presence of these fluid collections has any clinical relevance is 
unclear. The higher incidence of leakage might be caused by the difficulty of 
the laparoscopic suturing procedure. First of all this emphasizes the need for a 
dedicated laparoscopically trained surgeon to perform this procedure 
19
. 
Alternative techniques to simplify the suturing process have been thought of. 
19, 
48
. Some laparocopic surgeons use omentopexy alone 
18, 47
. Suture less 
techniques have been tried, in which fibrin glue alone or a gelatin sponge has 
been glued into the ulcer 
18
. The downside of this technique is that is only can 
be used to close small perforations. To overcome this problem a biodegradable 
patch, that can be cut into any desirable size, has been tested in rats, with good 
results 
50
. The combined laparoscopic-endoscopic repair also has been described 
as well 
51
. 
POSTOPERATIVE MANAGEMENT  
Reviewing literature all patients receive nasogastric draining for at least 
48 hrs 
16. This however seems to be more “common practice” than evidence 
based medicine 
49
. A routine nasogastric decompression does not achieve any of 
25 
 
its attended goals, should not applied to all and only be applied in selected 
cases, which has been supported by other trials as well 
51-54
.  
This also means that oral feeding can be started early, as in colorectal 
surgery and that waiting for three days, as often is done according to protocol, is 
unnecessary 
54-55
.  
Table 2 Post operative complications 
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As can be seen in Table 2 wound infections represent the second most 
common complication after surgery for PPU. Also the incidence of sepsis is 
2.5%. Preoperative intravenous administration of antibiotics has proven to 
lower the overall infection rate 
56
. Although for most surgical procedures a 
single dose seems to be sufficient, in case of H. pylori infection triple therapy is 
recommended consisting of a proton pump inhibitor combined with 
clarithromycin and amoxicillin for 14 days 
22, 33, 55, 56
. Upper gastrointestinal 
endoscopy is suggested to be performed after eight weeks to asses healing of the 
ulcers and to evaluate H.pylori status 
55
. 
                        
POSTOPERATIVE COMPLICATIONS.  
The postoperative complication most common observed was pneumonia, 
followed by wound infection. An overview of all complications and their 
incidences, based on reviewing literature are listed in table 2 
19, 22, 25, 26, 48, 49, 56-61
.  
                       
RISK FACTORS INFLUENCING OUTCOME  
Mortality after surgery for perforated peptic ulcer is between 6-10% 
26
. There 
are four main factors which can increase this mortality rate even up to 100%. 
These are  
 Age > 60 years,  
 Delayed treatment (>24hrs),  
27 
 
 Shock at time of the admission (systolic BP < 100 mmHg) and  
 Comorbid diseases 25, 27.  
Also gastric ulcers are associated with a two- to threefold increased mortality 
risk 
25, 27. Boey’s score, based on scoring factors as shock on admission, 
confounding medical illness, and prolonged perforation, has been found to be a 
useful tool in predicting outcome 
22, 29, 45, 57
. In the elderly mortality rate after 
surgery for PPU is three to five times higher and up to 50% 
61
. This can be 
explained by the occurrence of co morbid medical diseases and delay > 24 hrs 
due to difficulties making the right diagnosis. In case of a perforated gastric 
ulcer or recurrent PUD (hemi)gastrectomy with vagotomy might be indicated, 
but overall simple closure is a safe procedure and there seem to be no need for 
definitive surgery in this group of patients since ulcer recurrence is only 14% 
18, 
61, 62
.  
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MATERIALS AND METHODS 
 This study place was Department of General surgery, Rajivgandhi 
Government General Hospital attached to Madras Medical College, Chennai 
during the period of January 2013 to October 2013 
 The diagnosis of ulcer perforation was established by the admitting 
surgeon based on presenting complaints, clinical features and supported by 
radiological investigation and confirmed preoperatively. All patients of 
Duodenum part 1, Antrum, Pylorus and Prepyloric ulcer perforation are 
included in this study. 
 Patient factors Age, Sex, Clinical presentation including Pain site, 
Duration, Past peptic ulcer history and treatment, NSAID usage, Personal habits 
of smoking and consuming alcohol, Co morbid illnesses recorded. 
 Physical examination findings of Pulse rate, Respiratory rate, Blood 
pressure, Urine output monitored. Biochemical values of Urea, Creatinine, 
Electrolytes Sodium and Potassium, and Glucose level, Hematological values of 
Hemoglobin, Total count and Differential count noted. Duration between pain 
and surgery and admission and surgery were recorded.       
 ASA score, Laparotomy findings including site (Duodenum part 1, 
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Gastric antrum, Pylorus or Prepylorus), Size of perforation, Contamination 
volume and nature and procedure, Surgery duration recorded. 
 Post operative ventilator support, Cardiac support and Complications 
including Renal, Respiratory and Wound complications are followed and 
recorded. 
 Finally outcome of the surgery whether Death or Discharge and Total 
duration of hospital stay have been analyzed. Mortality means death following 
surgery within 28 days and morbidity means prolonged hospital stay and 
complications.   
EXCLUSION CRITERIA 
Cases of traumatic perforation 
Cases of gastric body and duodenum part 2 perforations 
Cases of iatrogenic perforations 
TOOLS USED 
The data were recorded in MS-excel and were analyzed using Statistical 
Package for Social Science (SPSS-16). The methods like Frequency analysis, 
Cross tabulation, Univariate and Multivariate analysis have been employed.   
 Following are the analysis of the study. 
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AGE GROUP 
 
Age                         FINAL  
                                     OUTCOME 
                Morbidity (hospital stay) 
Total 
<= 7 
days 
8-14 
days 
15-21 
days 
22-28 
days 
>= 29 
days 
Less than 20  Discharge   4     4 
% of Total  100.0%    100.0% 
20-39  Death  4 0 0 0 0 4 
% of Total 11.8% .0% .0% .0% .0% 11.8% 
Discharge  3 21 3 2 1 30 
% of Total 8.8% 61.8% 8.8% 5.9% 2.9% 88.2% 
40-59  Death  8 0 0   8 
% of Total 22.2% .0% .0%   22.2% 
Discharge  4 21 3   28 
% of Total 11.1% 58.3% 8.3%   77.8% 
60 and above  Death  10 2 0   12 
% of Total 38.5% 7.7% .0%   46.2% 
Discharge  0 13 1   14 
% of Total .0% 50.0% 3.8%   53.8% 
 
The above table shows the frequency of the patients age distribution. It is 
inferred that the patients whose age group is 60 and above are subject to death at 
large extent (46.2 percent) and their hospital stay is <=7 days due to death.  
 
The following table shows the Multivariate analysis to test the significance of 
Age on the Morbidity and Mortality of the patient. It is found that Age has 
significant effect on the Morbidity and Mortality of the patient as their 
31 
 
significant value is less than 5%. The size of the effect is 75.7 % on Morbidity 
and 10.3 % on Mortality. 
Multivariate analysis 
 
Source 
Dependent 
Variable 
Type III 
Sum of 
Squares Df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Age Morbidity 90.986 1 90.986 143.123 .000 .757 
Mortality .929 1 .929 5.272 .026 .103 
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SEX 
 
 
 
The number of Male and Female patients under the study are 98 and 2 
respectively are noted. 
                                
 
 
98 %
2 %
SEX
Male
Female
Sex                               Mortality 
Morbidity 
Total 
<=7 
days 
8-14 
days 
15-21 
days 
22-28 
days 
>=29 
days 
Male  Death Count 20 2 0 0 0 22 
% of Total 20.4% 2.0% .0% .0% .0% 22.4% 
Discharge Count 7 59 7 2 1 76 
% of Total 7.1% 60.2% 7.1% 2.0% 1.0% 77.6% 
Female  Death Count 2 
    
2 
% of Total 100.0%     100.0% 
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SITE OF PAIN 
 
 
Site of Pain No. of patients Percentage 
Epigastric pain 86 86.0 
All over abdomen 8 8.0 
LIF 2 2.0 
Diffuse 2 2.0 
Right Hypochondrium 2 2.0 
Total 100 100.0 
 
It is inferred from the above table that 86 % of the Patients had Epigastric pain 
and the remaining 12 % did not have the same. 
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PAIN DURATION 
 
Painduration                Mortality                              
Morbidity 
Total 
<= 7 
days
8-14 
days 
15-21 
days 
22-28 
days 
>= 29 
days 
<= 1 day  Death Count 2 2    4 
% of Total 6.2% 6.2%    12.5% 
Discharge Count 2 26    28 
% of Total 6.2% 81.2%    87.5% 
2 days  Death Count 4 0 0 0 0 4 
% of Total 14.3% .0% .0% .0% .0% 14.3% 
Discharge Count 2 17 3 1 1 24 
% of Total 7.1% 60.7% 10.7% 3.6% 3.6% 85.7% 
3 days  Death Count 10 0 0 0  10 
% of Total 35.7% .0% .0% .0%  35.7% 
Discharge Count 3 11 3 1  18 
% of Total 10.7% 39.3% 10.7% 3.6%  64.3% 
>=4 
days 
 Death Count 6 0 0   6 
% of Total 50.0% .0% .0%   50.0% 
Discharge Count 0 5 1   6 
% of Total .0% 41.7% 8.3%   50.0% 
 
The above table shows the cross tabulation of Pain duration, Morbidity and 
Mortality. It is observed from the following table that Pain duration in days has 
significant effect on the Mortality of the patient. And the size of the effect is 
10.3 percent. Whereas the Pain duration in days does not has any effect on the 
Morbidity of the patient. 
 
 
35 
 
Multivariate analysis 
Source 
Dependent 
Variable 
Type III 
Sum of 
Squares Df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Pain duration Mortality 1.883 3 .628 3.683 .015 .103 
Morbidity 2.762 3 .921 1.842 .145 .054 
 
    
 
    
PAIN DURATION IN DAYS 
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PAST HISTORY OF PEPTICULCER 
 
Past history of Pepticulcer No. of patients Percent 
Yes 82 82.0 
No 18 18.0 
Total 100 100.0 
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NSAID USAGE 
 
 
NSAID USAGE 
 
 
 
 
 
16%
84%
Yes
No
 
History of NSAID 
 
No. of patients 
 
Percent 
Yes 16 16.0 % 
No 84 84.0 % 
Total 100 100.0 
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SMOKING AND ALCOHOL HABITS 
 
 
Smoking and Alcohol habits No. of patients Percent 
Smoking only 6 6.0 % 
Consumes alcohol only 6 6.0 % 
Both smoking and Alcohol 48 48.0 % 
Neither smoking Nor alcohol 40 40.0 % 
Total 100 100.0 
 
 
 
SMOKING AND ALCOHOL HABITS 
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COMORBID ILLNESS 
 
Comorbid illness No. of patients Percent 
YES    BA 4 4.0 % 
   DCLD 2 2.0 % 
   DM,CRF 2 2.0 % 
   HIV,Hep B 2 2.0 % 
   PVD,BA 2 2.0 % 
NO 88 88.0 % 
Total 100 100.0 
 
 
RESPIRATORY DISTRESS (TACHYPNEA) 
 
Respiratory Distress No. of Patients Percent 
Yes 36 36.0 % 
No 64 64.0 % 
Total 100 100.0 
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ANEMIA 
 
Anemia Frequency Percent 
Yes 20 20.0 
No 80 80.0 
Total 100 100.0 
 
TACHYCARDIA & HYPOTENSION 
 
Tachycardia Hypotension No. of Patients Percent 
Tachycardia 38 38.0 % 
Both Tachycardia and Hypotension 26 26.0 % 
Neither Tachycardia nor hypotension 36 36.0 % 
Total 100 100.0 
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SHOCK 
 
Shock                         Mortality Morbidity 
Total 
<=7 days 8-14 
days 
15-21 
days 
22-28 
days 
>= 29 
days 
Class I  Death Count 0 2 0 0  2 
% of Total .0% 4.5% .0% .0%  4.5% 
Discharge Count 7 32 2 1  42 
% of Total 15.9% 72.7% 4.5% 2.3%  95.5% 
Class II  Death Count 6 0 0 0 0 6 
% of Total 20.0% .0% .0% .0% .0% 20.0% 
Discharge Count 0 18 4 1 1 24 
% of Total .0% 60.0% 13.3% 3.3% 3.3% 80.0% 
Class III  Death Count 16 0 0   16 
% of Total /61.5% .0% .0%   61.5% 
Discharge Count 0 9 1   10 
% of Total .0% 34.6% 3.8%   38.5% 
 
The above table shows the cross tabulation of Shock, Mortality and Morbidity 
of the patients under the purview of the study. Death is more in the patients who 
had class III shock.  
The Multivariate analysis has been done to test the significance of Shock on the 
Mortality and Morbidity of the patient. It is observed from the following table 
that the factor, Shock has significant effect on both the Mortality and Morbidity 
of the patient. The shock contributes 29.5 percent and 13.6 percent to the 
Mortality and Morbidity of the patient respectively. 
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Multivariate analysis 
Source 
Dependent 
Variable 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Shock Mortality 5.377 2 2.689 20.274 .000 .295 
Morbidity 6.908 2 3.454 7.642 .001 .136 
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PREOPERATIVE LRI 
Preoperative LRI         
Mortality      
Morbidity 
Total 
<= 7 
days 
8-14 
days 
15-21 
days 
22-28 
days 
>= 29 
days 
Yes   Death Count 8 0 0 
  
8 
% of Total 40.0% .0% .0% 
  
40.0% 
Discharge Count 0 11 1 
  
12 
% of Total .0% 55.0% 5.0% 
  
60.0% 
No  Death Count 14 2 0 0 0 16 
% of Total 17.5% 2.5% .0% .0% .0% 20.0% 
Discharge Count 7 48 6 2 1 64 
% of Total 8.8% 60.0% 7.5% 2.5% 1.2% 80.0% 
 
The cross tabulation of Preoperative LRI, Morbidity and Mobility of the 
patients under the study has been presented in the above table. The preoperative 
LRI is related to 40% of death. 
 
To test the significance of Preoperative LRI on the morbidity and Mortality of 
the patient, the Multivariate analysis has been adopted and presented in the 
following table. The result exhibit that the Preoperative LRI has significant 
effect on the Mortality of the patients as the significant values is less than 5 %. 
The Preoperative LRI contributes 33.5 percent to the Mortality. The 
preoperative LRI does not have any significant effect on the Morbidity. 
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Multivariate analysis 
 
Source 
Dependent 
Variable 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Preoperative 
LRI 
Mortality .640 1 .640 3.564 .042 .335 
Morbidity 1.000 1 1.000 1.970 .164 .020 
 
 
 
 
 
 
 
 
20%
80%
PREOPERATIVE LRI
Yes
No
45 
 
CXR AIR UNDER DIAPHARGM 
 
 
CXR AIR UNDER DIAPHARGM 
 
No. of Patients Percent 
Yes 76 76.0 % 
No 24 24.0 % 
Total 100 100.0 
 
BLOOD GLUCOSE 
 
Blood Glucose 
 
No. of Patients Percent 
<60 2 2.0 
60-120 82 82.0 
121-140 14 14.0 
>140 2 2.0 
Total 100 100.0 
 
 
UREA 
 
Urea No. of Patients Percent 
Normal (<=30) 38 38.0 
High (>30) 62 62.0 
Total 100 100.0 
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CREATININE 
 
Creatinine No. of Patients Percent 
Normal 54 54.0 
High 46 46.0 
Total 100 100.0 
 
 
SODIUM 
 
 
Sodium No. of Patients Percent 
Low (<136) 20 20.0 
Normal (136-146) 80 80.0 
Total 100 100.0 
 
 
 
POTTASSIUM 
 
 
Pottassium No. of Patients Percent 
 
Low (<3.5) 
 
14 
 
14.0 
Normal (3.5-5) 74 74.0 
High (>5) 12 12.0 
Total 100 100.0 
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TOTAL COUNT 
 
Total count No. of Patients Percent 
Low (<3000) 6 6.0 
Normal (3000-11000) 72 72.0 
High (>11000) 22 22.0 
Total 100 100.0 
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NEUTROPHILS 
 
Neutrophils No. of Patients Percent 
Low (<60%) 6 6.0 
Normal (60-70%) 18 18.0 
HIgh (>70%) 76 76.0 
Total 100 100.0 
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LYMPHOCYTES 
 
Lymphocytes No. of Patients Percent 
Low (<20%) 66 66.0 
Normal (20-30%) 22 22.0 
High (>30%) 12 12.0 
Total 100 100.0 
 
 
 
HEAMOGLOBIN 
 
 
Heamoglobin 
 
No. of Patients Percent 
Low (<12) 56 56.0 
Normal (12-16) 44 44.0 
Total 100 100.0 
 
50 
 
PERITONITIS 
 
 
Peritonitis 
 
No. of patients Percent 
Yes 94 94.0 
No 6 6.0 
Total 100 100.0 
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ASA SCORE 
 
ASAscore                                      Mortality 
Morbidity 
Total 
<= 7 
days 
8-14 
days 
15-21 
days 
22-28 
days 
>= 29 
days 
ASA score 1  Discharge Count 2 14 2 1 1 20 
% of Total 
10.0% 
70.0
% 
10.0% 5.0% 5.0% 
100.0
% 
ASA Score 2  Death Count 4 2 0 0  6 
% of Total 7.4% 3.7% .0% .0%  11.1% 
Discharge Count 5 38 4 1  48 
% of Total 
9.3% 
70.4
% 
7.4% 1.9% 
 
88.9% 
ASA Score 3  Death Count 14 0 0   14 
% of Total 63.6% .0% .0%   63.6% 
Discharge Count 0 7 1   8 
% of Total 
.0% 
31.8
% 
4.5% 
  
36.4% 
ASA Score 4  Death Count 2     2 
% of Total 
100.0% 
    100.0
% 
ASA Score 5  Death Count 2     2 
% of Total 
100.0% 
    100.0
% 
 
The above table shows the cross tabulation of ASA Score, Mortality and 
Morbidity of the patients selected under the study. ASA score of 4 and 5 had 
100% mortality and score of 3 had 64%.  
 
The following table shows that the ASA score has significant effect on both the 
Morbidity and Mortality of the patient as their significance value is less than 5 
% significance value. The effect of ASA score on the Mortality and Morbidity 
of the patient is 42.8 percent and 21.4 percent respectively. 
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Multivariate analysis 
Source 
Depende
nt 
Variable 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
ASA score Mortality 7.816 4 1.954 17.807 .000 .428 
Morbidity 10.848 4 2.712 6.457 .000 .214 
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DURATION BETWEEN PAIN AND SURGERY 
 
Duration- pain surgery           Mortality                
Morbidity 
Total 
<= 7 
days
8-14 
days 
15-21 
days 
22-28 
days 
>= 29 
days 
Less than 24 
hrs 
 Discharge Count  4    4 
% of Total  100.0%    100.0% 
24-48 hrs  Death Count 6 2 0   8 
% of Total 13.6% 4.5% .0%   18.2% 
Discharge Count 4 31 1   36 
% of Total 9.1% 70.5% 2.3%   81.8% 
49-72 hrs  Death Count 10 0 0 0 0 10 
% of Total 31.2% .0% .0% .0% .0% 31.2% 
Discharge Count 3 14 3 1 1 22 
% of Total 9.4% 43.8% 9.4% 3.1% 3.1% 68.8% 
Greater than 
72 hrs 
 Death Count 6 0 0 0  6 
% of Total 30.0% .0% .0% .0%  30.0% 
Discharge Count 0 10 3 1  14 
% of Total .0% 50.0% 15.0% 5.0%  70.0% 
 
 
The above table shows the cross tabulation between the Duration between pain 
and surgery, Morbidity and Mortality. Duration of more than 48 hrs between 
pain and surgery has significant mortality.  
It is inferred from the following table that the duration between pain and 
surgery has significant effect on the Mortality and Morbidity of the patient, as 
their significance values is greater than 5 %. 
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Multivariate analysis 
 
Source 
Dependent 
Variable 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Duration pain 
surgery 
Mortality .620 3 .207 1.125 .043 .034 
Morbidity .422 3 .141 .268 .048 .008 
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DURATION BETWEEN ADMISSION AND SURGERY 
 
DurationAdmnSurgery           
Mortality 
Morbidity 
Total 
<= 7 
days 
8-14 
days 
15-21 
days 
22-28 
days 
>= 29 
days 
<3 hrs  Death Count 8 0    8 
% of Total 50.0% .0%    50.0% 
Discharge Count 1 7    8 
% of Total 6.2% 43.8%    50.0% 
3-6 hrs  Death Count 10 0 0 0 0 10 
% of Total 19.2% .0% .0% .0% .0% 19.2% 
Discharge Count 4 30 5 2 1 42 
% of Total 7.7% 57.7% 9.6% 3.8% 1.9% 80.8% 
>6 hrs  Death Count 4 2 0   6 
% of Total 12.5% 6.2% .0%   18.8% 
Discharge Count 2 22 2   26 
% of Total 6.2% 68.8% 6.2%   81.2% 
 
 
Cross tabulation between the admission surgery duration, Mortality and 
Morbidity of the patient has been exhibited in the above table. To test the 
significance of Admission surgery duration on the mortality and morbidity of 
the patient, Multivariate analysis has been analyzed. The result has been 
exhibited in the following table. It is inferred that the duration between 
admission & surgery has a significant effect on the Mortality and Morbidity. 
The duration between admission and surgery has 17.1 % and 6.7% effect on the 
Mortality and Morbidity respectively. 
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Multivariate analysis 
 
Source 
Dependent 
Variable 
Type III 
Sum of 
Squares Df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
DurationAdmn 
Surgery 
Mortality 1.288 2 .644 3.685 .029 .171 
Morbidity 3.389 2 1.695 3.471 .035 .067 
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SITE OF PERFORATION 
 
Site of Perforation           Mortality 
Morbidity 
Total 
<= 7 
days 
8-14 
days 
15-21 
days 
22-28 
days 
>= 
29 
days Gastric  Death Count 
14 2 0 
 
0 16 
% of Total 
29.2% 4.2% .0% 
 
.0% 33.3% 
Discharge Count 
1 26 4 
 
1 32 
% of Total 
2.1% 54.2% 8.3% 
 
2.1% 66.7% 
Duodenum  Death Count 
8 0 0 0 
 
8 
% of Total 
15.4% .0% .0% .0% 
 
15.4% 
Discharge Count 
6 33 3 2 
 
44 
% of Total 
11.5% 63.5% 5.8% 3.8% 
 
84.6% 
 
 
The cross tabulation of frequency of Site of perforation, Morbidity and 
Mortality has been presented in the above table. The significance of Site of 
perforation to the Morbidity and Mobility has been exhibited in the below table. 
The result shows that the site of perforation is significant to the Mortality as the 
significance value is less than 5 %. On the other hand site of perforation is not 
significant to the Morbidity (Sig, 0.824 is > than .05). The size of effect of 
perforation is significant to the extent of 14.4 %. 
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Multivariate analysis 
 
Source 
Dependent 
Variable 
Type III 
Sum of 
Squares Df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Site of Perforation Mortality .804 1 .804 4.520 .036 .144 
Morbidity .026 1 .026 .050 .824 .001 
 
 
 
 
 
 
 
 
 
 
 
 
 
48%
52%
SITE OF PERFORATION
Gastric
Deodenum
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SIZE  
 
 
 
 
The frequency of the Size in cm, Morbidity and Mortality has been presented in 
the cross tabulation in the above table. It is observed in the following table that 
the size in cm has been significant on the Mortality to the extent of 12.9 percent 
and Morbidity has significant effect on the Morbidity to the extent of 6.6 
percent. Hence Size in cm significant to the Mortality and Morbidity of the 
patient. 
 
Sizeincm                              Mortality                                                                    
Morbidity 
Total 
<= 7 
days
8-14 
days
15-21 
days 
22-28 
days 
>= 29 
days 
Less than 1  Death Count 10 2 0 0 0 12 
% of Total 13.5% 2.7% .0% .0% .0% 16.2% 
Discharge Count 6 48 5 2 1 62 
% of Total 8.1% 64.9% 6.8% 2.7% 1.4% 83.8% 
1-3  Death Count 10 0 0   10 
% of Total 41.7% .0% .0%   41.7% 
Discharge Count 1 11 2   14 
% of Total 4.2% 45.8% 8.3%   58.3% 
More than 3  Death Count 2     2 
% of Total 100.0%     100.0% 
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Multivariate analysis 
 
Source Dependent 
Variable 
Type III 
Sum of 
Squares 
df Mean 
Square 
F Sig. 
 
Partial 
Eta 
Squared 
Size in cm 
Mortality 2.353 2 1.176 7.182 .001 .129 
      Morbidity 3.341 2 1.671 3.418 .037 .066 
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CONTAMINATION 
 
Contamination                   Mortality                           
Morbidity 
Total <= 7 
days 
8-14 
days 
15-21 
days 
22-28 
days 
>= 29 
days 
Less than 500ml  Death Count 2 0 0   2 
% of Total 8.3% .0% .0%   8.3% 
Discharge Count 2 19 1   22 
% of Total 8.3% 79.2% 4.2%   91.7% 
500 ml - 1 ltr  Death Count 6 2 0 0  8 
% of Total 13.6% 4.5% .0% .0%  18.2% 
Discharge Count 4 28 3 1  36 
% of Total 9.1% 63.6% 6.8% 2.3%  81.8% 
More than 1 ltr  Death Count 14 0 0 0 0 14 
% of Total 43.8% .0% .0% .0% .0% 43.8% 
Discharge Count 1 12 3 1 1 18 
% of Total 3.1% 37.5% 9.4% 3.1% 3.1% 56.2% 
 
The cross tabulation of contamination, Morbidity and Mortality has been 
presented in the cross tabulation in the above table. The following table shows 
the Multivariate analysis to check if the Contamination has any significant 
effect on the Mortality and Morbidity of the patient. It results that the 
Contamination has significant contribution to the Mortality and Morbidity. It is 
significant to the extent of 10.9 % and 9.04 % to the Mortality and Morbidity 
respectively. 
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Multivariate analysis 
 
Source 
Dependent 
Variable 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Contamination Mortality 1.986 2 .993 5.927 .004 .109 
 Morbidity .224 2 .112 .215 .007 .094 
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PROCEDURE 
 
Procedure                                  Mortality 
Morbidity 
Total 
<= 7 
days 
8-14 
days 
15-21 
days 
22-28 
days 
>= 29 
days 
Graham's  Death Count 8 0 0 0 0 8 
% of Total 
16.7% .0% .0% .0% .0% 16.7% 
Discharge Count 4 28 5 2 1 40 
% of Total 8.3% 58.3% 10.4% 4.2% 2.1% 83.3% 
Modified 
Graham's 
 Death Count 12 2 0   14 
% of Total 24.0% 4.0% .0%   28.0% 
Discharge Count 3 31 2   36 
% of Total 6.0% 62.0% 4.0%   72.0% 
Flank drain  Death Count 2     2 
% of Total 100.0%     100.0% 
 
  
 The frequency of the Procedure, Mortality and Morbidity has been cross 
tabulated above. To assess if the Procedure has any significant effect on the 
Morbidity and Mortality has been exhibited below. The result of the 
Multivariate analysis shows that the Procedure has no significant effect on the 
Mortality and Morbidity of the patient. 
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Multivariate analysis 
 
Source 
Dependent 
Variable 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Procedure Mortality 1.493 2 .747 4.325 .016 .082 
 Morbidity 3.130 2 1.565 3.188 .046 .062 
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SURGERY DURATION 
 
 
The frequency of the Duration of the surgery, Mortality and Morbidity has been 
cross tabulated above. To assess if the Surgery duration has any significant 
effect on the Morbidity and Mortality has been exhibited below. The result of 
the Multivariate analysis shows that the Surgery duration has significant effect 
on the Mortality of the patient (sig < 0.05). The size of the effect on the 
Mortality is 5.0 %. The surgery duration has no significant effect on the 
Morbidity of the patient as the significant value is less than 5 %. 
 
 
 
SurgeryDuration                   Mortality                              
Morbidity 
Total 
<= 7 
days 
8-14 
days 
15-21 
days 
22-28 
days 
>= 29 
days 
Between 1 
to 2 hr 
 Death Count 14 2 0 0 0 16 
% of Total 
17.1% 2.4% .0% .0% .0% 19.5% 
Discharge Count 7 50 6 2 1 66 
% of Total 8.5% 61.0% 7.3% 2.4% 1.2% 80.5% 
More than 
2 hr 
 Death Count 8 0 0   8 
% of Total 44.4% .0% .0%   44.4% 
Discharge Count 0 9 1   10 
% of Total .0% 50.0% 5.6%   55.6% 
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Multivariate analysis 
 
Source 
Dependent 
Variable 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
Partial 
Eta 
Squared 
Duration surgery Mortality .918 1 .918 5.191 .025 .050 
 Morbidity 1.253 1 1.253 2.480 .119 .025 
 
 
 
 
 
 
 
 
 
82%
18  %
DURATION SURGERY
Between 1 to 2 hr
More than 2 hr
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RESPIRATORY SUPPORT 
 
Respiratory support No. of Patients Percent 
Yes 
32 32.0 
No 
68 68.0 
Total 100 100.0 
 
 
 
RESPIRATORY SUPPORT 
 
 
32%
68%
RESPIRATORY SUPPORT
Yes 
No 
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CIRCULATORY SUPPORT 
 
Circulatory Support No. of Patients Percent 
Yes 24 24.0 
No 76 76.0 
Total 100 100.0 
 
 
RENAL FUNCTION 
 
Renal function No. of Patients Percent 
Adequate 76 76.0 
Not adequate 24 24.0 
Total 100 100.0 
 
RENAL FUNCTION 
 
76%
24%
Adequate
Not adequate
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INFECTION AND WOUND DEHISCENCE 
Infection and wound dehiscence No. of Patients Percent 
Infection 20 20.0 
Both Infection and Wound Dehiscence 26 26.0 
No infection and would dehiscence 44 44.0 
Could not assess due to death 10 10.0 
Total 100 100.0 
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RESPIRATORY COMPLICATION 
Respiratory complication No. of Patients Percent 
YES ARDS 10 10.0 
LRI 20 20.0 
PE 4 4.0 
PE,LRI 4 4.0 
NO 62 62.0 
Total 100 100.0 
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RENAL COMPLICATION 
Renal complication No. of Patients Percent 
YES AKI 16 10.0 
Prerenal 6 20.0 
Renal 8 4.0 
NO 62 62.0 
Total 100 100.0 
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MODS 
 
MODS No. of Patients Percent 
YES 14 14.0 
NO 86 86.0 
Total 100 100.0 
 
 
 
 
 
14%
86%
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No
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CAUSE OF DEATH 
 
Cause of death Frequency Percent 
AKI 4 16.7 
ARDS 1 4.2 
MODS 10 41.7 
SEPTIC SHOCK 9 37.5 
Total 24 100.0 
 
CAUSE OF DEATH AND DURATION OF HOSPITAL STAY 
  
DURATION OF HOSPITAL STAY 
T
o
ta
l 
 CAUSE OF DEATH 
<= 7 
days 
8-14 
days 
15-21 
days 
22-28 
days 
>= 29 
days 
 
AKI 2 2 0 0 0 4 
ARDS 1 0 0 0 0 1 
MODS 10 0 0 0 0 10 
SEPTIC SHOCK 9 0 0 0 0 9 
% 91.7% 8.3% - - - 24 
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CROSS TABULATION ON MORBIDITY (DURATION OF HOSPITAL 
STAY) AND FINAL OUTCOME 
 
CROSS TABULATION ON MORBIDITY AND FINAL OUTCOME 
Morbidity 
Total 
Final 
Outcome 
 
 
 
Final outcome 
<=7 days 
8-14 
days 
15-21 
days 
22-28 
days 
>= 29 
days 
Death 
Count 22 2 0 0 0 24 
% of Total 22.0% 2.0% .0% .0% .0% 24.0% 
Discharge 
Count 7 59 7 2 1 76 
% of Total 7.0% 59.0% 7.0% 2.0% 1.0% 76.0% 
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DISCUSSION 
 Age of 60 years and above had mortality of 46% and also this mortality is 
high within the first 48 hrs and up to 7 days. Average duration of hospital 
stay was 7 to 14 days which includes 59% regarding all age group. 
Multivariate analysis showed age has significant effect on the mortality 
(P = 0.000) and morbidity (P = 0.026). 
 Female sex was more related to severe disease and mortality (100%). 
 Most of the patients initially presented with epigastric pain (86%). 
 Duration of pain of 3 or more days when presenting to hospital had 
related to mortality. Duration of 3 days had 35.7% and 4 or more 50% 
mortality. Duration of pain has significant effect on mortality (P = 0.15) 
 82% of the patients had past history of peptic ulcer and on and off 
treatment. 
 Only 16% of patients had history of NSAID usage before perforation. 
 48% of patients had the habit of both smoking and alcohol and 40% are 
neither smoking nor alcoholic. 
 On physical examination 96% had respiratory distress, 80% had anemia, 
38% had tachycardia, 26% both hypotension and tachycardia, and 36% 
had normal pulse and blood pressure. 
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 Patients who had Class 3 shock at the time of admission had 66% 
mortality. Shock has significant effect on both morbidity (P = 0.001) and 
mortality (P = 0.000).  
 Preoperative lower respiratory infection had 40% mortality. Preoperative 
LRI had significant effect on mortality (P = 0.042). 
 Biochemical analysis of serum showed 62% high urea and 46% high 
creatinine. Hyponatremia and hypokalemia was seen in 20% and 14% of 
the patients. 
 Hematological evaluation showed 72% of patients had normal leucocyte 
count but more towards higher end and 76% had high neutrophill 
percentage around 90%. 
 On examination of abdomen 94% had signs of peritonitis and obliteration 
of liver dullness in 80% of patients. 
 Chest Xray showed air under diaphragm in 76% of the patients. 
 Duration between pain and surgery that is preoperative delay of more 
than 48 hours has significant effect on mortality (P = 0.042) and 
morbidity (P = 0.043). 48 to 72 hours had 31% and more than 72 hrs had 
32% mortality.   
 Duration between admission and surgery related to final outcome is 
influenced by duration between initial pain and surgery. 
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 ASA score of 4 and 5 had 100% mortality and score of 3 had 64%. It has 
significant on mortality (P = 0.000) and morbidity (P = 0.000) 
 Gastric perforation (30%) has more mortality than duodenal (20%) 
perforation. 
 Size of perforation more than 1 cm has 42% mortality and it has 
significant effect on mortality and morbidity 
 Contamination of more than 1 litre had significantly influences in 
mortality (P = 0.004) and morbidity (P = 0.0070. In our observation more 
than 1 litre related to 44% of death.  
 Duration of the surgery more than 2 hours had significant effect on the 
mortality (P = 0.025)  
 32% of the patients were not extubated and continued on ventilator 
support and 24% were in need of circulatory support. 
 76% of patients had adequate renal function. 
 46% of the patients developed wound infection and 26% had wound 
dehiscence and underwent secondary suturing. No wound infection in 
44%. 
 Post operatively 20% patients had lower respiratory infection and 10% 
had ARDS leading to death. 
 24% of the patient had acute kidney injury and treated with supportive 
treatment. 6% had prerenal failure and treated with intravenous fluids. 
78 
 
 14% of patients had developed multiple organ dysfunctions and died. 
 Sepsis leading to shock and multiple organ dysfunctions is a cause of 
death. 
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CONCLUSION 
THE FOLLOWING FACTORS WERE ASSOCIATED WITH MORBIDITY 
 AND MORTALITY 
 
 Age more than 60 years 
 Duration between initial pain and surgery of more than 48 hours 
 Class III or more shock 
 ASA score of 3and more 
 Size of more than 1 cm 
 Contamination of more than 1 litre 
THE FOLLOWING FACTORS WERE ASSOCIATED WITH MORTALITY 
 Preoperative lower respiratory infection 
 Duration of the surgery 
 Post operative lower respiratory infection 
 Acute respiratory distress syndrome 
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PROFORMA 
Name :         IP. No:                       Age : 
Address:                                       Sex : 
 
 
            
  
         
Occupation:               
DOA & Time:               
DOS & Time:               
DOD:                 
Chief complaints: Abdominal pain site           
     Started on & Time:           
Treatment history: For present illness: Yes/No         
    Type of treatment:           
    Duration:              
Past history: Peptic ulcer disease:           
    Drugs used:           
    Surgery for peptic ulcer:         
Personal history: Smoking, duration:           
    Alcohol, duration:           
    Dietary habit:           
Co morbid illness: HT / DM / CLD / CRF / TB         
    COPD/CVA           
General examination             
  Conscious             
  Orientation             
  Hydration             
  Fever               
  Jaundice               
  Anemia               
  Respiratory distress             
Vitals                 
  PR:               
  BP:               
  Temp:               
  RR:               
Systemic examination:             
  CVS:               
  RS:               
  Abdomen             
Investigations :             
  CXR               
  USG               
Biochemistry  Glucose             
    Urea             
    creatinine            
    Na+             
    K+             
  CBC TC:             
    DC:             
    Platelets:             
DIAGNOSIS               
Treatment:               
PRE operative: Peritonitis             
    Shock             
    ASA score           
Duration between pain and surgery:           
PER operative:               
  Surgery   : open / lap         
  Site of perforation             
  Size 
: <1cm / 1 – 3cm / 
>3cm             
  Contamination              
  Procedure done             
  Duration of procedure           
  Drainage               
POST Operative period             
  Respiratory support             
  Circulatory support             
  Renal function             
Complications :             
  Leakage               
  Fluid collection             
  Paralytic ileus             
  Intestinal obstruction           
  Bleeding               
  Wound complication           
  Pulmonary complication:           
  Cardiac complication           
  Renal complication             
  Hepatic complication           
  Multi organ failure             
  Others               
FINAL OUTCOME             
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1 Dhamodaran 16 M Y   1 Y Y N N N Y N Y N Y Y 3 Y Y     
2 Arasu 55 M Y   1 Y Y Y Y PVD,BA N N N N Y N 2 Y N     
3 Venkatesh 28 M N LIF 2 N Y Y Y HIV,HepB Y Y Y N Y Y 3 Y Y     
4 Joseph 70 M Y   3 Y N Y Y N Y Y N N Y Y 3 N N     
5 Subramani 60 M N allover 2 Y N Y N N Y N N N Y N 2 N Y     
6 Hussain 60 M Y   10 Y N N N N Y Y N N N N 1 N Y     
7 Narayanasamy 65 M Y   2 N N Y Y N N N N N N N 1 N Y     
8 Maruthu 40 M Y   3 Y N N N N N N N N N N 1 N Y     
9 Paneer selvam 56 M Y   3 Y N N N N N N N N Y N 2 N Y     
10 Kanimozhi 45 F Y   3 N Y N N N Y Y N N Y Y 3 Y N     
11 Palani 60 M Y   7 Y N Y Y DCLD Y Y N Y Y Y 3 Y Y     
12 Krishnamoorthy 55 M Y   2 Y N Y Y N Y N N N Y Y 3 N Y     
13 Selvam 60 M Y   7 Y N Y Y N Y N N N Y N 2 Y N     
14 Murugesan 30 M N Diffuse 1 N N N Y N N N N N N N N N Y     
15 Muna 25 M Y   2 Y N Y Y N N N N N N N N N Y     
16 Sriram 45 M Y   2 Y N N N N N Y N N Y Y 3 N Y     
17 Nagendran 50 M Y   3 Y N Y Y N N N N N Y N 2 N Y     
18 Kamaraj 38 M Y   1 Y N Y Y BA N N N N Y Y 3 Y Y     
19 Sighumalick 21 M Y   3 Y N N N N N Y Y N Y N 2 N Y     
20 Mani 55 M Y   3 Y N Y Y N N N N N Y Y 2 N Y     
21 Rangachari 65 M Y   1 Y N Y Y DM, CRF N N N N N N 1 N Y     
22 Pintu 25 M Y   3 Y N N N N N N N N N N 1 N Y     
23 Kumar 26 M Y   3 Y N N Y N N N N N Y N 1 N Y     
24 Siva 40 M Y   1 Y N Y Y N N N N N N N 1 N Y     
25 Arulraj 40 M Y   3 Y N N N N N N N N N N 1 N N     
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26 Kumar 40 M Y   1 Y N Y N N N N N N N N 1 N Y     
27 Paramasivam 41 M N RtHC 2 Y N N N N N N Y N Y N 1 N N     
28 Masilamani 16 M Y   1 N Y N N N N N N N N N 1 N N   FA 
29 Prakash 24 M Y   3 Y N Y Y N Y N N N Y N 2 N Y     
30 Saravanan 35 M N allover 2 Y N Y Y N Y N N N Y N 2 N Y     
31 Sivakumar 25 M Y   2 Y N N N N N N N N N N 1 N Y     
32 Abshiek kumar 24 M N allover 2 Y N N N N N N N N N N 1 N N FF   
33 Gangan 35 M Y   3 Y N N N N N N N N N N 1 N Y     
34 Elumalai 40 M Y   2 Y N Y Y N N N N N Y N 1 N Y     
35 Manikandan 22 M Y   1 Y N N N N N N N N N N 1 N Y     
36 Kumar 37 M Y   6hrs y n Y Y N N N N N Y N 2 N Y     
37 Ettiyappan 70 M N allover 4 Y N N Y N N N N N Y N 2 N N FF   
38 Devaraj 54 M Y   4 Y N Y Y N Y N N N Y Y 3 N Y     
39 Babu 40 M Y   1 Y N Y Y N N N N N Y N 2 N Y     
40 Murugan 53 M Y   1 N N N N N N N N N N N 2 N Y     
41 Santhanam 23 M Y   3 Y N Y Y N N N N N Y N 1 N Y     
42 Arumugam 48 M Y   1 N N N N N N N N N Y N 1 N N     
43 Fakrudeen 79 M Y   1 Y N N N N Y N N N Y Y 3 N Y     
44 Anbarasan 25 M Y   1 Y Y N N N Y N Y N Y Y 3 Y Y     
45 Jeyachandran 55 M Y   1 Y Y Y Y BA N N N N Y N 2 Y N     
46 Rajagopal 28 M Y   2 N Y Y Y N Y Y Y N Y Y 3 Y Y     
47 Siva 70 M Y   3 Y N Y Y N Y Y N N Y Y 3 N N     
48 Kasi 60 M Y   2 Y N Y N N Y N N N Y N 2 N Y     
49 Baskar 60 M Y   10 Y N N N N Y Y N N N N 1 N Y     
50 Bala 65 M Y   2 N N Y Y N N N N N N N N N Y     
 
S.No NAME AGE  SEX 
EP
IG
A
ST
R
IC
 P
A
IN
 
O
TH
ER
 S
IT
ES
 
P
A
IN
 D
U
R
A
TI
O
N
 in
 
D
A
YS
 
P
A
ST
 h
is
to
ry
 o
f 
P
EP
TI
C
 U
LC
ER
 
h
is
to
ry
 o
f 
N
SA
ID
 
SM
O
K
IN
G
 
A
LC
O
H
O
L 
C
O
M
O
R
B
ID
 IL
LN
ES
S 
R
ES
P
IR
A
TO
R
Y 
D
IS
TR
ES
S 
A
N
EM
IA
 
FE
V
ER
 
JA
U
N
D
IC
E 
TA
C
H
YC
A
R
D
IA
 
H
YP
O
TE
N
SI
O
N
 
SH
O
C
K
 C
LA
SS
 
P
re
 o
p
er
aa
ti
ve
 L
R
I 
C
X
R
 A
IR
 u
n
d
er
 
d
ia
p
h
ar
gm
 
U
SG
 
C
EC
T 
51 Ramadoss 18 M Y   1 Y Y N N N Y N Y N Y Y 3 Y Y     
52 Lakshmanan 56 M Y   1 Y Y Y Y PVD,BA N N N N Y N 2 Y N     
53 Vishalkumar 28 M N LIF 2 N Y Y Y HIV,HepB Y Y Y N Y Y 3 Y Y     
54 Krishnapillai 72 M Y   3 Y N Y Y N Y Y N N Y Y 3 N N     
55 Raj  60 M N Allover 2 Y N Y N N Y N N N Y N 2 N Y     
56 Radhakrishnan 60 M Y   10 Y N N N N Y Y N N N N 1 N Y     
57 Appuraj 67 M Y   2 N N Y Y N N N N N N N N N Y     
58 Purusothaman 40 M Y   3 Y N N N N N N N N N N N N Y     
59 Gopal 58 M Y   3 Y N N N N N N N N Y N 2 N Y     
60 Raji 48 F Y   3 N Y N N N Y Y N N Y Y 3 Y N     
61 Ravikumar 60 M Y   7 Y N Y Y DCLD Y Y N Y Y Y 3 Y Y     
62 Gnanamoorthy 56 M Y   2 Y N Y Y N Y N N N Y Y 3 N Y     
63 Moorthy 62 M Y   7 Y N Y Y N Y N N N Y N 2 Y N     
64 Yesuraj 34 M N Diffuse 1 N N N Y N N N N N N N N N Y     
65 Jeyaraman 28 M Y   2 Y N Y Y N N N N N N N N N Y     
66 Balaji 49 M Y   2 Y N N N N N Y N N Y Y 3 N Y     
67 Lingaiyan 54 M Y   3 Y N Y Y N N N N N Y N 2 N Y     
68 Srinivasan 42 M Y   1 Y N Y Y BA N N N N Y Y 3 Y Y     
69 Bindy 26 M Y   3 Y N N N N N Y Y N Y N 2 N Y     
70 Shankar 58 M Y   3 Y N Y Y N N N N N Y Y 2 N Y     
71 Sabiq 66 M Y   1 Y N Y Y DM, CRF N N N N N N 1 N Y     
72 Rangan 28 M Y   3 Y N N N N N N N N N N 1 N Y     
73 Kesavan 29 M Y   3 Y N N Y N N N N N Y N 1 N Y     
74 Premkumar 43 M Y   1 Y N Y Y N N N N N N N 1 N Y     
75 Ahamed 40 M Y   3 Y N N N N N N N N N N 1 N N     
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76 Manoharan 40 M Y   1 Y N Y N N N N N N N N 1 N Y     
77 Chandran 44 M N RtHC 2 Y N N N N N N Y N Y N 1 N N     
78 Tarunkumar 18 M Y   1 N Y N N N N N N N N N 1 N N   FA 
79 Rajendran 29 M Y   3 Y N Y Y N Y N N N Y N 2 N Y     
80 Suriyakumar 37 M N allover 2 Y N Y Y N Y N N N Y N 2 N Y     
81 Sivaraj 26 M Y   2 Y N N N N N N N N N N 1 N Y     
82 Gokul 28 M N allover 2 Y N N N N N N N N N N 1 N N FF   
83 Pandian 39 M Y   3 Y N N N N N N N N N N 1 N Y     
84 Manimaran 40 M Y   2 Y N Y Y N N N N N Y N 1 N Y     
85 Sandhanagopal 22 M Y   1 Y N N N N N N N N N N 1 N Y     
86 Ganesan 37 M Y   6HRS y n Y Y N N N N N Y N 2 N Y     
87 Ganapathy 70 M N allover 4 Y N N Y N N N N N Y N 2 N N FF   
88 Muruganantham 54 M Y   4 Y N Y Y N Y N N N Y Y 3 N Y     
89 Barani 34 M Y   1 Y N Y Y N N N N N Y N 2 N Y     
90 Nithyanandham 53 M Y   1 N N N N N N N N N N N 2 N Y     
91 Rajesh 23 M Y   3 Y N Y Y N N N N N Y N 1 N Y     
92 Ramkumar 48 M Y   1 N N N N N N N N N Y N 1 N N     
93 Abdulla 79 M Y   1 Y N N N N Y N N N Y Y 3 N Y     
94 Anduraj 25 M Y   1 Y Y N N N Y N Y N Y Y 3 Y Y     
95 Prabakaran 55 M Y   1 Y Y Y Y BA N N N N Y N 2 Y N     
96 Rajan 28 M Y   2 N Y Y Y N Y Y Y N Y Y 3 Y Y     
97 Smith 70 M Y   3 Y N Y Y N Y Y N N Y Y 3 N N     
98 Devanathan 60 M Y   2 Y N Y N N Y N N N Y N 2 N Y     
99 Mani 60 M Y   10 Y N N N N Y Y N N N N 1 N Y     
100 Periyasamy 65 M Y   2 N N Y Y N N N N N N N N N Y     
USG - Ultrasonagram 
CT - Computerised 
Tomography 
FF - Free fluid 
FA - Free air 
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1 Dhamodaran 107 68 1.7 141 4.2 15700 74 15 11 Y 2 33 3.3 O PP 0.5 0.5 B MG 2 
2 Arasu 96 22 0.8 137 4.6 9200 90 9 13 Y 2 32 7.3 O A 0.5 1 B MG 1.3 
3 Venkatesh 96 69 2 145 5.1 2500 56 15 8 Y 3 52 2.45 O A 0.5 1 B MG 2.3 
4 Joseph 86 65 2.1 146 4.8 7800 90 9 9 Y 3 57 2.3 O D1 3 2 GAN MG 1.3 
5 Subramani 126 125 1.5 137 3.6 6900 91 6 12 Y 3 28 4 O P  0.5 0.5 PUS G 2.3 
6 Hussain 110 28 1.1 140 4 9800 78 25 9 Y 2 10 DAYS 12 O D1 0.5 0 B G 2.3 
7 Narayanasamy 126 36 1 142 3.9 10400 72 14 11 Y 2 58 8 O D1 0.5 0.05 B MG 2 
8 Maruthu 110 26 0.9 131 3.6 7700 70 20 12 Y 2 75 2 O D1 0.5 1.5 B MG 2 
9 Paneer selvam 68 132 4.2 138 5.4 14400 74 24 11 Y 3 82 10 O A 1.5 0.8 PUS G 2.5 
10 Kanimozhi 106 106 3.2 130 5.9 15600 90 9 8 Y 5 96 13 O A 1 2 B G 2 
11 Palani 90 56 2.1 140 3.7 12000 88 13 8 Y 3 7 days 3 O A 0.5 3 B MG 3 
12 Krishnamoorthy 70 101 5.1 139 3 6400 90 7 11 Y 3 72 11 O A 1 3 B G 2 
13 Selvam 91 74 1.6 136 3.5 7200 60 35 13 Y 2 7 days 7 O PP 0.5 1 B MG 1.3 
14 Murugesan 98 28 0.8 138 3.7 11600 60 38 9.8 Y 2 26 1.3 O D1 0.5 0.5 B MG 2 
15 Muna 114 44 1.1 139 3.3 9500 83 12 13 Y 2 52 5 O D1 0.5 2.5 B G 2 
16 Sriram 60 34 1.1 140 3.4 7500 84 9 11 Y 2 53 5 O D1 1 2 B G 2 
17 Nagendran 87 40 1 131 3.8 3700 90 8 13 Y 2 76 4.3 O D1 0.3 0.8 B G 2.3 
18 Kamaraj 153 42 0.7 132 4.8 3400 60 34 13 Y 2 30 7 O D1 0.5 2 B G 1.5 
19 Sighumalick 114 40 0.9 128 4.6 5600 90 7 12 Y 2 17 5 O D1 1 0.5 B G 1.3 
20 Mani 90 45 2.1 136 4.6 11600 78 20 11 Y 2 39 3 O A 0.5 1 B G 1.3 
21 Rangachari 69 98 3.2 142 5.8 6800 90 8 9.6 Y 2 30 18 O PP 0.5 0.75 B MG 1.3 
22 Pintu 90 38 1 137 3.8 10400 68 30 11 Y 2 45 9 O D1 0.5 1 B G 1.3 
23 Kumar 108 28 0.9 138 3.8 7100 77 15 10 Y 2 41 5 O D1 1 1 B G 2 
24 Siva 108 26 0.9 135 3.6 10200 82 12 12 Y 2 30 5 O D1 0.5 1 B G 1 
25 Arulraj 110 28 1.2 134 3 11000 63 30 12 Y 2 42 6 O P 1 1 B MG 2 
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26 Kumar 106 46 1.1 137 3.6 10600 90 9 11 Y 2 27 3 O D1 0.5 1 B G 1.3 
27 Paramasivam 120 28 1.5 133 4.6 8100 80 12 12 N 2 51 3.15 O D1 0.3 0.1 B G 1.3 
28 Masilamani 94 25 0.8 138 3.8 9700 76 20 12 N 1 31 7.45 O A 0.4 0.3 B MG 1.45 
29 Prakash 132 28 0.8 138 4.8 11400 93 7 16 Y 1 76 3 O D1 0.4 0.5 B G 1.45 
30 Saravanan 82 64 2.5 136 4 4000 96 5 14 Y 1 53 5 O A 0.5 3 B G 1.3 
31 Sivakumar 98 28 0.9 133 3.7 10100 86 10 14 Y 1 52 4 O A 0.5 0.5 B MG 1.45 
32 Abshiekkumar 80 44 1.3 142 3.8 10000 72 23 12 N 1 56 8 O D1 0.5 0.3 B MG 1.3 
33 Gangan 132 30 1,3 139 3.2 5000 57 37 14 Y 1 75 4 O D1 0.5 0.5 B G 1.3 
34 Elumalai 185 23 0.7 136 2.5 5900 63 33 13 Y 1 52 2 O D1 1 1.5 B MG 2 
35 Manikandan 106 28 0.7 136 3.6 10500 72 27 11 Y 1 28 3.3 O A 1 2 B G 2 
36 Kumar 96 36 1.5 142 4.1 5800 84 14 9.2 Y 1 12 5.3 O D1 0.5 0.2 B G 2 
37 Ettiyappan 80 69 4.3 143 4 5500 60 35 6.3 Y 3 72 5.3 O D1 0.5 2 B MG 1.3 
38 Devaraj 90 67 3 145 4 7800 89 11 7 Y 4 24 6 O - - 2 B DRAIN 1 
39 Babu 83 28 0.8 140 3.8 7200 88 10 11 Y 2 28 4 O P 0.5 0.2 B MG 1.2 
40 Murugan 114 28 0.9 134 3.5 2600 70 29 16 Y 2 26 2 O D1 0.7 1.5 B MG 2 
41 Santhanam 120 28 0.8 141 3 12100 80 10 9.6 Y 3 80 8 O PP 0.3 1 B MG 1.3 
42 Arumugam 59 34 1.2 143 3.6 19700 92 6 13 Y 1 29 5.3 O P 0.4 1 B MG 2 
43 Fakrudeen 67 155 2.9 136 5.2 15900 92 4 9.6 Y 2 30 5 O D1 2 3 B G 2 
44 Anbarasan 107 68 1.7 141 4.2 15700 74 15 11 Y 2 33 3.3 O PP 0.5 0.5 B MG 2 
45 Jeyachandran 96 22 0.8 137 4.6 9200 90 9 13 Y 2 32 7.3 O A 0.5 1 B MG 1.3 
46 Rajagopal 96 69 2 145 5.1 2500 56 15 8 Y 3 52 2.45 O A 0.5 1 B MG 2.3 
47 Siva 86 65 2.1 146 4.8 7800 90 9 9 Y 3 57 2.3 O D1 3 2 GAN MG 1.3 
48 Kasi 126 125 1.5 137 3.6 6900 91 6 12 Y 3 28 4 O P  0.5 0.5 PUS G 2.3 
49 Baskar 110 28 1.1 140 4 9800 78 25 9 Y 2 10 DAYS 12 O D1 0.5 0 B G 2.3 
50 Bala 126 36 1 142 3.9 10400 72 14 11 Y 2 58 8 O D1 0.5 0.05 B MG 2 
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51 Ramadoss 107 68 1.7 141 4.2 15700 74 15 11 Y 2 33 3.3 O PP 0.5 0.5 B MG 2 
52 Lakshmanan 96 22 0.8 137 4.6 9200 90 9 13 Y 2 32 7.3 O A 0.5 1 B MG 1.3 
53 Vishalkumar 96 69 2 145 5.1 2500 56 15 8 Y 3 52 2.45 O A 0.5 1 B MG 2.3 
54 Krishnapillai 86 65 2.1 146 4.8 7800 90 9 9 Y 3 57 2.3 O D1 3 2 GAN MG 1.3 
55 Raj  126 125 1.5 137 3.6 6900 91 6 12 Y 3 28 4 O P  0.5 0.5 PUS G 2.3 
56 Radhakrishnan 110 28 1.1 140 4 9800 78 25 9 Y 2 10 DAYS 12 O D1 0.5 0 B G 2.3 
57 Appuraj 126 36 1 142 3.9 10400 72 14 11 Y 2 58 8 O D1 0.5 0.05 B MG 2 
58 Purusothaman 110 26 0.9 131 3.6 7700 70 20 12 Y 2 75 2 O D1 0.5 1.5 B MG 2 
59 Gopal 68 132 4.2 138 5.4 14400 74 24 11 Y 3 82 10 O A 1.5 0.8 PUS G 2.5 
60 Raji 106 106 3.2 130 5.9 15600 90 9 8 Y 5 96 13 O A 1 2 B G 2 
61 Ravikumar 90 56 2.1 140 3.7 12000 88 13 8 Y 3 7 days 3 O A 0.5 3 B MG 3 
62 Gnanamoorthy 70 101 5.1 139 3 6400 90 7 11 Y 3 72 11 O A 1 3 B G 2 
63 Moorthy 91 74 1.6 136 3.5 7200 60 35 13 Y 2 7 days 7 O PP 0.5 1 B MG 1.3 
64 Yesuraj 98 28 0.8 138 3.7 11600 60 38 9.8 Y 2 26 1.3 O D1 0.5 0.5 B MG 2 
65 Jeyaraman 114 44 1.1 139 3.3 9500 83 12 13 Y 2 52 5 O D1 0.5 2.5 B G 2 
66 Balaji 60 34 1.1 140 3.4 7500 84 9 11 Y 2 53 5 O D1 1 2 B G 2 
67 Lingaiyan 87 40 1 131 3.8 3700 90 8 13 Y 2 76 4.3 O D1 0.3 0.8 B G 2.3 
68 Srinivasan 153 42 0.7 132 4.8 3400 60 34 13 Y 2 30 7 O D1 0.5 2 B G 1.5 
69 Bindy 114 40 0.9 128 4.6 5600 90 7 12 Y 2 17 5 O D1 1 0.5 B G 1.3 
70 Shankar 90 45 2.1 136 4.6 11600 78 20 11 Y 2 39 3 O A 0.5 1 B G 1.3 
71 Sabiq 69 98 3.2 142 5.8 6800 90 8 9.6 Y 2 30 18 O PP 0.5 0.75 B MG 1.3 
72 Rangan 90 38 1 137 3.8 10400 68 30 11 Y 2 45 9 O D1 0.5 1 B G 1.3 
73 Kesavan 108 28 0.9 138 3.8 7100 77 15 10 Y 2 41 5 O D1 1 1 B G 2 
74 Premkumar 108 26 0.9 135 3.6 10200 82 12 12 Y 2 30 5 O D1 0.5 1 B G 1 
75 Ahamed 110 28 1.2 134 3 11000 63 30 12 Y 2 42 6 O P 1 1 B MG 2 
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76 Manoharan 106 46 1.1 137 3.6 10600 90 9 11 Y 2 27 3 O D1 0.5 1 B G 1.3 
77 Chandran 120 28 1.5 133 4.6 8100 80 12 12 N 2 51 3.15 O D1 0.3 0.1 B G 1.3 
78 Tarunkumar 94 25 0.8 138 3.8 9700 76 20 12 N 1 31 7.45 O A 0.4 0.3 B MG 1.45 
79 Rajendran 132 28 0.8 138 4.8 11400 93 7 16 Y 1 76 3 O D1 0.4 0.5 B G 1.45 
80 Suriyakumar 82 64 2.5 136 4 4000 96 5 14 Y 1 53 5 O A 0.5 3 B G 1.3 
81 Sivaraj 98 28 0.9 133 3.7 10100 86 10 14 Y 1 52 4 O A 0.5 0.5 B MG 1.45 
82 Gokul 80 44 1.3 142 3.8 10000 72 23 12 N 1 56 8 O D1 0.5 0.3 B MG 1.3 
83 Pandian 132 30 1,3 139 3.2 5000 57 37 14 Y 1 75 4 O D1 0.5 0.5 B G 1.3 
84 Manimaran 185 23 0.7 136 2.5 5900 63 33 13 Y 1 52 2 O D1 1 1.5 B MG 2 
85 Sandhanagopal 106 28 0.7 136 3.6 10500 72 27 11 Y 1 28 3.3 O A 1 2 B G 2 
86 Ganesan 96 36 1.5 142 4.1 5800 84 14 9.2 Y 1 12 5.3 O D1 0.5 0.2 B G 2 
87 Ganapathy 80 69 4.3 143 4 5500 60 35 6.3 Y 3 72 5.3 O D1 0.5 2 B MG 1.3 
88 Muruganantham 90 67 3 145 4 7800 89 11 7 Y 4 24 6 O - - 2 B drain 1 
89 Barani 83 28 0.8 140 3.8 7200 88 10 11 Y 2 28 4 O P 0.5 0.2 B MG 1.2 
90 Nithyanandham 114 28 0.9 134 3.5 2600 70 29 16 Y 2 26 2 O D1 0.7 1.5 B MG 2 
91 Rajesh 120 28 0.8 141 3 12100 80 10 9.6 Y 3 80 8 O PP 0.3 1 B MG 1.3 
92 Ramkumar 59 34 1.2 143 3.6 19700 92 6 13 Y 1 29 5.3 O P 0.4 1 B MG 2 
93 Abdulla 67 155 2.9 136 5.2 15900 92 4 9.6 Y 2 30 5 O D1 2 3 B G 2 
94 Anduraj 107 68 1.7 141 4.2 15700 74 15 11 Y 2 33 3.3 O PP 0.5 0.5 B MG 2 
95 Prabakaran 96 22 0.8 137 4.6 9200 90 9 13 Y 2 32 7.3 O A 0.5 1 B MG 1.3 
96 Rajan 96 69 2 145 5.1 2500 56 15 8 Y 3 52 2.45 O A 0.5 1 B MG 2.3 
97 Smith 86 65 2.1 146 4.8 7800 90 9 9 Y 3 57 2.3 O D1 3 2 B MG 1.3 
98 Devanathan 126 125 1.5 137 3.6 6900 91 6 12 Y 3 28 4 O P  0.5 0.5 PUS G 2.3 
99 Mani 110 28 1.1 140 4 9800 78 25 9 Y 2 10 DAYS 12 O D1 0.5 0 B G 2.3 
100 Periyasamy 126 36 1 142 3.9 10400 72 14 11 Y 2 58 8 O D1 0.5 0.05 B MG 2 
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CAUSE OF 
DEATH 
1 Dhamodaran N N A  N N N N N N N LRI N N N N Discharge 11 - 
2 Arasu N N A N N N N N N N N N N N N Discharge 10 - 
3 Venkatesh Y Y NA               ARDS ARREST AKI N Y Death 1 Septic shock 
4 Joseph Y Y NA               ARDS ARREST AKI N Y Death 1 Septic shock 
5 Subramani N N A N N N N N N N N N AKI N N Discharge 10   
6 Hussain N N A N N N N N N N N N N N N Discharge 13   
7 Narayanasamy N N A N N Y N N N N LRI N N N N Discharge 14   
8 Maruthu n n A n n n n n n n n n n n n Discharge 9   
9 Paneer selvam Y Y NA N N n n n Y n LRI n AKI n n Death 6 AKI 
10 Kanimozhi y y NA n n n n n y n n n n N Y Death 5 MODS 
11 Palani y y NA n n n n n Y y n N prerenal n n Death 1 Septic shock 
12 Krishnamoorthy y y A n n n n n y y PE N prerenal n n Discharge 16   
13 Selvam y N A n n n n n Y Y PE,LRI N prerenal n n Discharge 18   
14 Murugesan n n A n n n n n n n n N n n n Discharge 10   
15 Muna n n A n Y n n n Y y PE,LRI N n n n Discharge 23   
16 Sriram n n A n n n n n n n N N n n n Discharge 13   
17 Nagendran n n A n n n n n Y Y N N n n n Discharge 15   
18 Kamaraj y n A n n n n n y y LRI N n n n Discharge 11   
19 Sighumalick n n A n n n n n y n N N n n n Discharge 10   
20 Mani Y n A n n n n n n N ARDS N n n n Death 3 Septic shock 
21 Rangachari Y n NA n n n n n y N LRI N Renal n n Death 10 AKI 
22 Pintu n n A n n n n n n n N N n n n Discharge 8   
23 Kumar n n A n n n n n n n N N n n n Discharge 8   
24 Siva n n A n n n n n n n N N n n n Discharge 13   
25 Arulraj n n A n Y Y n n n N PE N n n n Discharge 18   
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26 Kumar N N A N N N N N N N N N N N N Discharge 9   
27 Paramasivam N N A N N N N N N N N N N N N Discharge 9   
28 Masilamani N N A N N N N N Y N N N N N N Discharge 11   
29 Prakash N N A N N N N N Y Y N N N N N Discharge 25   
30 Saravanan Y Y NA N N N N N Y N Y Y AKI N N Discharge 30   
31 Sivakumar N N A N N N N N Y N N N N N N Discharge 14   
32 Abshiek kumar N N A N N N N N Y N N N N N N Discharge 9   
33 Gangan N N A N N N N N N N N N N N N Discharge 11   
34 Elumalai N N A N N N N N Y N N N N N N Discharge 13   
35 Manikandan N N A N N N N N N N N N N N N Discharge 10   
36 Kumar N N A N N N N N N N N N N N N Discharge 10   
37 Ettiyappan Y Y NA N N N N N N N LRI N RENAL N Y Death 7 MODS 
38 Devaraj Y Y NA - - - - - - - - - RENAL - Y Death 1 Septic shock 
39 Babu N N A N N N N N N N N N N N N Discharge 10   
40 Murugan N N A N N N N N N N N N N N N Discharge 14   
41 Santhanam N N A N N N N N Y N N N N N N Discharge 10   
42 Arumugam N N A N N N N N N N N N N N N Discharge 8   
43 Fakrudeen Y Y NA N N N N N N N LRI N RENAL N N Death 2 Septic shock 
44 Anbarasan N N A  N N N N N N N LRI N N N N Discharge 11   
45 Jeyachandran N N A N N N N N N N N N N N N Discharge 10   
46 Rajagopal Y Y NA               ARDS ARREST AKI N Y Death 1 MODS 
47 Siva Y Y NA               ARDS ARREST AKI N Y Death 1 MODS 
48 Kasi N N A N N N N N N N N N AKI N N Discharge 10   
49 Baskar N N A N N N N N N N N N N N N Discharge 13   
50 Bala N N A N N Y N N N N LRI N N N N Discharge 14   
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51 Ramadoss N N A  N N N N N N N LRI N N N N Discharge 11 - 
52 Lakshmanan N N A N N N N N N N N N N N N Discharge 10 - 
53 Vishalkumar Y Y NA               ARDS ARREST AKI N Y Death 1 MODS 
54 Krishnapillai Y Y NA               ARDS ARREST AKI N Y Death 1 MODS 
55 Raj  N N A N N N N N N N N N AKI N N Discharge 10   
56 Radhakrishnan N N A N N N N N N N N N N N N Discharge 13   
57 Appuraj N N A N N Y N N N N LRI N N N N Discharge 14   
58 Purusothaman n n A n n n n n n n n n n n n Discharge 9   
59 Gopal Y Y NA N N n n n Y n LRI n AKI n n Death 6 AKI 
60 Raji y y NA n n n n n y n n n n N Y Death 5 MODS 
61 Ravikumar y y NA n n n n n Y y n N prerenal n n Death 1 Septic shock 
62 Gnanamoorthy y y A n n n n n y y PE N prerenal n n Discharge 16   
63 Moorthy y N A n n n n n Y Y PE,LRI N prerenal n n Discharge 18   
64 Yesuraj n n A n n n n n n n n N n n n Discharge 10   
65 Jeyaraman n n A n Y n n n Y y PE,LRI N n n n Discharge 23   
66 Balaji n n A n n n n n n n n N n n n Discharge 13   
67 Lingaiyan n n A n n n n n Y Y n N n n n Discharge 15   
68 Srinivasan y n A n n n n n y y LRI N n n n Discharge 11   
69 Bindy n n A n n n n n y n n N n n n Discharge 10   
70 Shankar Y n A n n n n n n N ARDS N n n n Death 3 ARDS 
71 Sabiq Y n NA n n n n n y N LRI N Renal n n Death 10 AKI 
72 Rangan n n A n n n n n n n n N n n n Discharge 8   
73 Kesavan n n A n n n n n n n n N n n n Discharge 8   
74 Premkumar n n A n n n n n n n n N n n n Discharge 13   
75 Ahamed n n A n Y Y n n n N PE N n n n Discharge 18   
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CAUSE OF 
DEATH 
76 Manoharan N N A N N N N N N N N N N N N Discharge 9   
77 Chandran N N A N N N N N N N N N N N N Discharge 9   
78 Tarunkumar N N A N N N N N Y N N N N N N Discharge 11   
79 Rajendran N N A N N N N N Y Y N N N N N Discharge 25   
80 Suriyakumar Y Y NA N N N N N Y N Y Y AKI N N Discharge 30   
81 Sivaraj N N A N N N N N Y N N N N N N Discharge 14   
82 Gokul N N A N N N N N Y N N N N N N Discharge 9   
83 Pandian N N A N N N N N N N N N N N N Discharge 11   
84 Manimaran N N A N N N N N Y N N N N N N Discharge 13   
85 Sandhanagopal N N A N N N N N N N N N N N N Discharge 10   
86 Ganesan N N A N N N N N N N N N N N N Discharge 10   
87 Ganapathy Y Y NA N N N N N N N LRI N RENAL N Y Death 7 MODS 
88 Muruganantham Y Y NA - - - - - - - - - RENAL - Y Death 1 Septic shock 
89 Barani N N A N N N N N N N N N N N N Discharge 10   
90 Nithyanandham N N A N N N N N N N N N N N N Discharge 14   
91 Rajesh N N A N N N N N Y N N N N N N Discharge 10   
92 Ramkumar N N A N N N N N N N N N N N N Discharge 8   
93 Abdulla Y Y NA N N N N N N N LRI N RENAL N N Death 2 Septic shock 
94 Anduraj N N A  N N N N N N N LRI N N N N Discharge 11   
95 Prabakaran N N A N N N N N N N N N N N N Discharge 10   
96 Rajan Y Y NA               ARDS ARREST AKI N Y Death 1 MODS 
97 Smith Y Y NA               ARDS ARREST AKI N Y Death 1 MODS 
98 Devanathan N N A N N N N N N N N N AKI N N Discharge 10   
99 Mani N N A N N N N N N N N N N N N Discharge 13   
100 Periyasamy N N A N N Y N N N N LRI N N N N Discharge 14   
 
